NEW YORK, NY--(Marketwire - August 16, 2012) - Alliqua, Inc. (OTCBB: ALQA) (“Alliqua” or the “Company”), an advanced biopharmaceutical company focused on the development, manufacturing and distribution of proprietary transdermal wound care and drug delivery technologies, today announced the addition of Dr. Harold Schoenhaus to Alliqua’s Scientific Advisory Board (“SAB”).
As a board certified surgeon by the American Board of Podiatric Surgery, and the American Board of Podiatric Orthopedics, Dr. Schoenhaus brings over 40 years of experience in the fields of Podiatric and Orthopedic Medicine to the SAB of Alliqua. Dr. Schoenhaus is currently a Professor at Temple University School of Podiatric Medicine and an attending physician at Penn-Presbyterian Medical Center where he serves as Podiatric Director of the Penn Wound Care Center. Dr. Schoenhaus is the former Chairman of the Department of Foot and Ankle Surgery at Graduate Hospital, Philadelphia and Past President of The American College of Foot and Ankle Surgeons. As a result of his extensive medical experience in academics and research, including numerous articles in such publications as the Journal of the American Podiatric Association and the Journal of Foot and Ankle Surgery, Dr. Schoenhaus is a highly sought after lecturer, advisor and consultant to the medical industry. He has served in a consulting or advisory capacity to companies such as Dow Corning, OsteoMed and EBI (a subsidiary of Biomet).
Commenting on his new advisory role at Alliqua, Dr. Schoenhaus stated, “I am pleased to become a part of the team at Alliqua by becoming a member of the SAB. As a practicing surgeon, I am keenly aware of the need and potential for Alliqua’s SilverSeal®, silver based, hydrogel wound dressings for a wide variety of applications. I am most excited by the commercialization potential for the technology platform. Transdermal delivery of drugs or other agents in the medical industry alone creates a wealth of opportunities for this company for years to come and I look forward to helping this company capitalize on the opportunities ahead.”
Richard Rosenblum, President of Alliqua, added: “We are excited to welcome Dr. Schoenhaus to our team of advisors at Alliqua. As we continue to put the pieces in place to build our company into a world class organization, the addition of Dr. Schoenhaus will provide a tremendous wealth of experience to help guide our future. His hands-on experience in the use of wound care products and his impeccable reputation in the medical industry will make him a tremendous asset to Alliqua for the advancement of our SilverSeal® products as well as our future transdermal drug delivery initiatives.”
About Alliqua, Inc.
Alliqua, Inc. (OTCBB: ALQA) (“Alliqua”) is an advanced biopharmaceutical company focused on the development, manufacturing and distribution of our proprietary transdermal wound care and drug delivery technologies. Alliqua’s leading technology platform produces hydrogels, a three dimensional cross-linked network of water soluble polymers capable of numerous chemical configurations. We currently market our new line of 510K FDA approved hydrogel products for wound care under our SilverSeal® brand. Due to our unique electron beam production process at our 16,000 square foot GMP manufacturing facility, we can aggressively develop and custom manufacture a wide variety of hydrogels. Our hydrogels can be customized for various transdermal applications to address multi-billion dollar market opportunities in the treatment of wounds such as diabetic ulcers, as well as the delivery of numerous drugs or other agents for the pharmaceutical and cosmetic industries. By using our drug delivery platform in combination with certain drugs, pharmaceutical companies can increase patient compliance as well as potentially extend the life of valuable drug patents. For additional information, please visit www.alliqua.com. To receive future press releases via email, please visit: http://alliqua.com/index.php?page=investor-alerts.
Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the our control that can make such statements untrue, including, but not limited to, inadequate capital, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K filed with the SEC on March 29, 2012 and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.
Contact:
Alliqua, Inc.
Steven Berger
646-218-1450
